PO.TB10.08 · 肿瘤生物学
利用Xenium转录组学与Hyperion XTi成像质谱流式对肿瘤-免疫微环境进行综合多组学分析
Comprehensive multi-omic profiling of the tumor-immune microenvironment using Xenium transcriptomics and Hyperion XTi Imaging Mass Cytometry
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
空间多组学已成为解析细胞异质性和精确表征组织微环境的强大策略,超越了仅RNA或仅蛋白空间检测所能达到的生物学分辨率。为解决单一模态分析的局限性,我们建立了一个整合工作流程,将Xenium原位转录组学与Standard BioTools的Hyperion XTi成像质谱流式(IMC)系统相结合。该方法旨在实现同一组织区域内转录组和蛋白质组特征的协调、高参数分析,支持对微环境结构和功能的更深入研究。使用由胃大细胞癌、结肠腺癌、浸润性导管癌和肺鳞状细胞癌组成的人原发FFPE多组织面板,BioChain生成了空间分辨的Xenium转录组数据,并利用谱系定义标志物绘制了细胞群体图谱。识别了主要的上皮、间质、内皮、淋巴和髓系区室,并勾勒了结构特征——包括肿瘤巢、间质边界、三级淋巴结构和混合免疫聚集体。对每个感兴趣区域,将转录组读出提炼为简明的微环境概要,反映免疫浸润强度、淋巴组织化、细胞毒活性、间质组成和检查点相关转录程序。这些区域级图谱使得能够在异质性肿瘤类型间进行微环境类别的跨组织比较。对相同组织区域的Hyperion XTi IMC分析提供了具有高空间和表型分辨率的互补蛋白质组视图。扩展的蛋白面板解析了与免疫激活、抑制、增殖和组织重塑相关的功能状态。重叠的免疫和间质标志物支持将蛋白质组信号与Xenium转录组图谱对齐,使得能够跨模态引用相应的细胞邻域。总之,这些数据集建立了一个多组学空间框架,在共享的组织坐标内将细胞身份与蛋白水平的功能动态联系起来。总体而言,这种转录组-蛋白质组联合策略为利用有限的FFPE材料进行综合空间分析建立了一个可扩展且实用的模板。该工作流程与现有分析工具兼容,易于适配新面板或组织类型,并为未来开发空间信息生物标志物及对复杂组织生态系统的机制性洞察奠定了良好基础。
查看英文原文 English abstract
Spatial multi-omics has become a powerful strategy for resolving cellular heterogeneity and precisely characterizing the tissue microenvironment, surpassing the biological resolution achievable with RNA-only or protein-only spatial assays. To address the limitations of single-modality profiling, we established an integrated workflow that combines Xenium in situ transcriptomics with Standard BioTools' Hyperion XTi Imaging Mass Cytometry (IMC) system. This approach is designed to enable coordinated, high-parameter analysis of transcriptomic and proteomic features within the same tissue regions, supporting deeper investigation of microenvironmental structure and function. Using a human primary FFPE multi-tissue panel comprising stomach large cell carcinoma, colon adenocarcinoma, invasive ductal carcinoma, and lung squamous cell carcinoma, BioChain generated spatially resolved Xenium transcriptomic data and mapped cell populations using lineage-defining markers. Major epithelial, stromal, endothelial, lymphoid, and myeloid compartments were identified, and architectural features-including tumor nests, stromal boundaries, tertiary lymphoid structures, and mixed immune aggregates-were delineated. For each region of interest, transcriptomic readouts were distilled into concise microenvironmental summaries reflecting immune infiltration intensity, lymphoid organization, cytotoxic activity, stromal composition, and checkpoint-associated transcriptional programs. These region-level profiles enabled cross-tissue comparison of microenvironmental classes across heterogeneous tumor types. Hyperion XTi IMC profiling of the same tissue regions provided a complementary proteomic view with high spatial and phenotypic resolution. The expanded protein panel resolved functional states associated with immune activation, suppression, proliferation, and tissue remodeling. Overlapping immune and stromal markers supported alignment of proteomic signals with the Xenium transcriptomic map, allowing corresponding cellular neighborhoods to be referenced across modalities. Together, these datasets established a multi-omic spatial framework that links cellular identity to protein-level functional dynamics within shared tissue coordinates. Overall, this combined transcriptomic-proteomic strategy establishes a scalable and practical template for comprehensive spatial profiling using limited FFPE material. The workflow is compatible with existing analysis tools, readily adaptable to new panels or tissue types, and well positioned for future development of spatially informed biomarkers and mechanistic insights into complex tissue ecosystems.
利益披露 Disclosure
W. Smith,
Standard BioTools Inc. Employment.
E. Cheung,
BioChain Institute Inc. Employment.
J. Tian,
BioChain Institute Inc. Independent Contractor.
Q. Raza,
Standard BioTools Inc. Employment.
T. Astill,
Standard BioTools Inc. Employment.
D. Zangrando,
Standard BioTools Inc. Employment.
N. Lane,
Standard BioTools Inc. Employment.
T. Tran,
BioChain Institute Inc. Employment.
R. Gakhar,
BioChain Institute Inc. Employment.
V. Sundaram,
BioChain Institute Inc. Employment.